SEATTLE, July 31,
2024 /PRNewswire/ -- TwinStrand Biosciences today
announced an agreement with Exact Sciences (Nasdaq: EXAS), a
leading provider of cancer screening and diagnostic tests, to
exclusively license its patent estate in the cell free nucleic acid
sequencing space, including its patent portfolios licensed from the
University of Washington and the
University of Texas Southwestern.
The license is related to TwinStrand Duplex
Sequencing® error-correction technology, which increases
the accuracy of next-generation sequencing by as much as 10,000
times, allowing the detection of ultra-low frequency mutations that
would otherwise be hidden by technical noise inherent to the
sequencing process. This agreement provides Exact Sciences the
ability to use, commercialize, and sublicense the intellectual
property acquired under the license. Exact Sciences' rights are
broadly exclusive with respect to cell free nucleic acid
sequencing, subject to certain non-exclusive relationships in the
field.
"This agreement with TwinStrand represents a significant
advancement in Exact Sciences' ability to pioneer new frontiers in
early cancer detection and precision oncology," said Kevin
Conroy, CEO of Exact Sciences. "By integrating with TwinStrand's
innovative technology, Exact Sciences will be better equipped to
accelerate the pace of discovery and delivery of even more precise
and reliable cancer diagnostic solutions to patients and healthcare
providers worldwide."
"Exact Sciences is an excellent partner to commercialize and
sublicense our patented technology, and with it they will advance
diagnostic accuracy, particularly in the areas of cancer detection
and monitoring," said Chad Waite,
Chairman of TwinStrand Biosciences.
About TwinStrand Biosciences
TwinStrand Biosciences'
Duplex Sequencing is the foundational technology enabling the
ability to accurately identify ultra-low frequency genomic variants
that are undetectable by conventional NGS methods. The company's
highly sensitive and specific, patented Duplex Sequencing
technology delivers clearer insights to researchers and clinicians
in applications ranging from residual cancer detection to genetic
toxicology. This data can inform critical decisions in clinical
medicine, public health, and other fields of science on a faster
timescale when actions are most impactful. TwinStrand's
scientist-leaders have authored more than thirty peer-reviewed
articles using Duplex Sequencing technology and have developed a
portfolio of more than 150 patents and patent applications. The
company has partnered with pharmaceutical companies, academic
centers, clinical research networks, molecular diagnostic
companies, and federal regulatory agencies to bring high precision
genomics to the forefront of their science. For more information
visit www.twinstrandbio.com.
About Exact Sciences
A leading provider of cancer
screening and diagnostic tests, Exact Sciences gives patients and
health care professionals the clarity needed to take life-changing
action earlier. Building on the success of the
Cologuard® and Oncotype® tests, Exact
Sciences is investing in its pipeline to develop innovative
solutions for use before, during, and after a cancer diagnosis. For
more information, visit ExactSciences.com, follow Exact Sciences on
X (formerly known as Twitter) @ExactSciences, or find Exact
Sciences on LinkedIn and Facebook.
TwinStrand Biosciences Contact
Media and
Investors:
Karen Dabbs
kdabbs@twinstrandbio.com
Exact Sciences Contacts
Media:
Morry Smulevitz
msmulevitz@exactsciences.com
608-345-8010
Investors:
Erik Holznecht
investorrelations@exactsciences.com
608-800-6605
View original content to download
multimedia:https://www.prnewswire.com/news-releases/twinstrand-biosciences-and-exact-sciences-announce-exclusive-license-agreement-for-duplex-sequencing-technology-302211267.html
SOURCE TwinStrand Biosciences